1150617-53-0

Basic information

• Product Name: BenzenaMine, 3-broMo-N-Methyl-2-nitro-
• Synonyms: BenzenaMine, 3-broMo-N-Methyl-2-nitro-;3-broMo-N-Methyl-2-nitroaniline;3-BroMo-n-Methyl-2-nitrobenzenaMine;2-Bromo-6-(methylamino)nitrobenzene, N-(3-Bromo-2-nitrophenyl)methylamine;(3-Bromo-2-nitro-phenyl)-methyl-amine
• CAS NO: 1150617-53-0
• Molecular Formula: C₇H₇BrN₂O₂
• Molecular Weight: 231.04668
• Mol File: 1150617-53-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 298.115 °C at 760 mmHg
• Flash Point: 134.096 °C
• Appearance: /
• Density: 1.688 g/cm³
• CAS DataBase Reference: BenzenaMine, 3-broMo-N-Methyl-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzenaMine, 3-broMo-N-Methyl-2-nitro-(1150617-53-0)
• EPA Substance Registry System: BenzenaMine, 3-broMo-N-Methyl-2-nitro-(1150617-53-0)

Safety Data

• Hazardous Substances Data: 1150617-53-0(Hazardous Substances Data)

Usage

General Description

BenzenaMine, 3-bromo-N-Methyl-2-nitro- is a chemical compound with the molecular formula C7H7BrN2O2. It is commonly used in organic synthesis and pharmaceutical research. BenzenaMine, 3-broMo-N-Methyl-2-nitro- is a derivative of aniline, containing a bromine and a nitro group attached to the benzene ring. It has potential applications in the development of new drugs, agrochemicals, and dyes. However, it is important to handle this compound with caution due to its potentially harmful effects on human health and the environment.

Upstream product

• 74-89-5 methylamine 
• 886762-70-5 2?bromo?6?fluoronitrobenzene 

Downstream Products

• 1150617-55-2 3-bromo-N¹-methylbenzene-1,2-diamine 
• 1239719-55-1 4-bromo-2-(4-fluorophenyl)-1-methyl-1H-benzimidazole 
• 1381869-30-2 4-bromo-2-(3-methoxyphenyl)-1-methyl-1H-benzoimidazole 

Relevant articles and documents

Fragment Based Optimization of Metabotropic Glutamate Receptor 2 (mGluR2) Positive Allosteric Modulators in the Absence of Structural Information

Metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulators (PAMs) have been implicated as potential pharmacotherapy for psychiatric conditions. Screening our corporate compound deck, we identified a benzotriazole fragment (4) that was rapidly optimized to a potent and metabolically stable early lead (16). The highly lipophilic character of 16, together with its limited solubility, permeability, and high protein binding, however, did not allow reaching of the proof of concept in vivo. Since further attempts on the optimization of druglike properties were unsuccessful, the original hit 4 has been revisited and was optimized following the principles of fragment based drug discovery (FBDD). Lacking structural information on the receptor-ligand complex, we implemented a group efficiency (GE) based strategy and identified a new fragment like lead (60) with more balanced profile. Significant improvement achieved on the druglike properties nominated the compound for in vivo proof of concept studies that revealed the chemotype being a promising PAM lead targeting mGluR2 receptors.

Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent γ-Secretase Modulators

The design and the synthesis of several chemical subclasses of imidazole containing γ-secretase modulators (GSMs) is described. Conformational restriction of pyridone 4 into bicyclic pyridone isosteres has led to compounds with high in vitro and in vivo p

NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS

The present invention is concerned with novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives of Formula (I) wherein R1, R2, R3, R4, X, A1, A2, A3, A4, Y1, Y2, Y3 and Z have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.